This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: stub-manual Compound SKIP-PERMANENT HIGH

Cyclazodone

Extended Research
High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-PERMANENT — risk:benefit fails for the canonical archetype.

Extended Research

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

Editor's verdict SKIP-PERMANENT HIGH

Parent compound pemoline was withdrawn from US market in 2005 because of fatal hepatotoxicity. Cyclazodone shares the oxazolidinone scaffold and has zero clinical safety data. Multiple anecdotal forum reports of liver enzyme elevation with chronic cyclazodone use. SKIP-PERMANENT — pharmaceutical stimulants (Adderall, Vyvanse, methylphenidate) are vastly safer if a prescription path is appropriate.

Research pass: stub-manual
Verdict change log
  • 2026-06-05 — Initial verdict SKIP-PERMANENT. (stub)

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…